Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Isocitrate dehydrogenase mutations in myeloid malignancies
Bruno C. Medeiros, Amir T. Fathi, Courtney D. DiNardo, et al.
Leukemia (2016) Vol. 31, Iss. 2, pp. 272-281
Open Access | Times Cited: 311

Showing 1-25 of 311 citing articles:

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, et al.
Blood (2017) Vol. 130, Iss. 6, pp. 722-731
Open Access | Times Cited: 1319
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Xiaoyun Li, Mathias Wenes, Pedro Romero, et al.
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 7, pp. 425-441
Closed Access | Times Cited: 577
The emerging role and targetability of the TCA cycle in cancer metabolism
Nicole Anderson, Patrick Mucka, Joseph G. Kern, et al.
Protein & Cell (2017) Vol. 9, Iss. 2, pp. 216-237
Open Access | Times Cited: 447
Advances in acute myeloid leukemia
Laura F. Newell, Rachel J. Cook
BMJ (2021), pp. n2026-n2026
Open Access | Times Cited: 310
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Matthew S. Waitkus, Bill H. Diplas, Hai Yan
Cancer Cell (2018) Vol. 34, Iss. 2, pp. 186-195
Open Access | Times Cited: 285
Molecular biomarkers in acute myeloid leukemia
Jeanette Prada-Arismendy, Johanna C. Arroyave-Ospina, Sarah Röthlisberger
Blood Reviews (2016) Vol. 31, Iss. 1, pp. 63-76
Closed Access | Times Cited: 276
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Ina Nepstad, Kimberley Joanne Hatfield, Ida Sofie Grønningsæter, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2907-2907
Open Access | Times Cited: 245
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis
Ying Qing, Lei Dong, Lei Gao, et al.
Molecular Cell (2021) Vol. 81, Iss. 5, pp. 922-939.e9
Open Access | Times Cited: 234
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub, Nishanth S. Iyengar, Siddhant Dogra, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 215
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism
Soojeong Chang, Sujin Yim, Hyunsung Park
Experimental & Molecular Medicine (2019) Vol. 51, Iss. 6, pp. 1-17
Open Access | Times Cited: 189
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development
Lenny Dang, Shinsan M. Su
Annual Review of Biochemistry (2017) Vol. 86, Iss. 1, pp. 305-331
Open Access | Times Cited: 186
Targeting mitochondrial metabolism for precision medicine in cancer
Lourdes Sainero‐Alcolado, Judit Liaño-Pons, María Victoria Ruiz-Pérez, et al.
Cell Death and Differentiation (2022) Vol. 29, Iss. 7, pp. 1304-1317
Open Access | Times Cited: 185
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, et al.
Blood (2020) Vol. 137, Iss. 13, pp. 1792-1803
Open Access | Times Cited: 181
The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues
Eric S. Goetzman, Edward V. Prochownik
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 174
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Guillermo Garcia‐Manero, Kelly S. Chien, Guillermo Montalban‐Bravo
American Journal of Hematology (2020) Vol. 95, Iss. 11, pp. 1399-1420
Open Access | Times Cited: 165
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 165
Application of Next Generation Sequencing in Laboratory Medicine
Yiming Zhong, Feng Xu, Jinhua Wu, et al.
Annals of Laboratory Medicine (2020) Vol. 41, Iss. 1, pp. 25-43
Open Access | Times Cited: 160
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, et al.
Journal of Clinical Oncology (2020) Vol. 39, Iss. 1, pp. 57-65
Open Access | Times Cited: 156
The Roles of 2-Hydroxyglutarate
Xin Du, Hai Hu
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 106
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 94
Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer
Rawan Al‐Faze, Hoda A. Ahmed, Mohamed A. El‐Atawy, et al.
Biomedical Journal (2024), pp. 100714-100714
Open Access | Times Cited: 19
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Jorge E. Cortés, Gail J. Roboz, Maria R. Baer, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Enasidenib: First Global Approval
Esther Kim
Drugs (2017) Vol. 77, Iss. 15, pp. 1705-1711
Closed Access | Times Cited: 151
Emerging therapies for acute myeloid leukemia
Caner Saygin, Hetty E. Carraway
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 137
Page 1 - Next Page

Scroll to top